Search Results - "Terol Castera, Maria Jose"

Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study by Bravo, Julio, Baltasar Tello, Patricia, González Garcia, Esther, Ríos Herranz, Eduardo, Páyer, Angel Ramirez, Terol Castera, María José, Champ, Diana, Medina Perez, Angeles, Gironella, Mercedes, Fernández Zarzoso, Miguel, Forés, Rafael, Delgado, Julio, Garcia-Marco, José A.

“…GABRIELL was a phase II single-arm study to evaluate the efficacy and safety of obinutuzumab plus bendamustine for relapsed/refractory (R/R) chronic…”
Get full text

Digital PCR Assay for Evaluation of CD19-CAR-T Cells In Vivo Expansion in Aggressive B-Cell Lymphoma: Impact on Clinical Outcome by Ventura, Laura, Serrano, Alicia, Ferrer Lores, Blanca, Hernani, Rafael, Vasile Tudorache, Alexandru Robert, Teruel, Ana Isabel, Saus Carreres, Ana, Ortiz Algarra, Alfonso, Arroyo Martin, Ignacio, Hernandez Boluda, Juan Carlos, Pinana Sanchez, Jose Luis, Perez, Ariadna, Benzaquen, Ana, Solano, Carlos, Terol Castera, Maria Jose

“…Background: Chimeric antigen receptor (CAR)-T cells therapy has revolutionized hematological treatment mainly in non-Hodgkin lymphoma (NHL) demonstrating…”
Get full text

Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy by Mei, Matthew G., Corazzelli, Gaetano, Morschhauser, Frank, Phillips, Elizabeth, Collins, Graham P., Lee, Hun Ju, Ansell, Steve M, Moskowitz, Craig H., Johnson, Nathalie A., Kuruvilla, John, Hutchings, Martin, Terol Castera, María José, Hawkins, George, Vossenkaemper, Anna, Collins, Teresa, Lesley, Robin, Dean, Emma, Yu, Ting, Hall, Connor, Cerec, Virginie, Zinzani, Pier Luigi

“…Background Immunotherapies targeting the PD-1/PD-L1 pathway have been shown to induce high response rates in patients with relapsed/refractory (r/r) classical…”
Get full text

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) by Garcia-Marco, Jose, Baltasar Tello, Patricia, Garcia, Esther González, Ríos Herranz, Eduardo, Ramirez Payer, Angel, Terol Castera, María José, Champ, Diana, Medina Perez, Angeles, Gironella, Mercedes, Rodríguez Fernández, Alicia, Muntañola Prat, Ana, Suárez Cabrera, Alexia, Jurado Chacón, Manuel, Fernández Zarzoso, Miguel, Rodríguez, Mercedes, Clavel, Juana, Dourdil Sahun, Maria Victoria, Ferra Coll, Christelle M, Pérez Persona, Ernesto, Marrero Santos, Carmen Milagros, Forés, Rafael, Delgado, Julio

“…Introduction: The use of combined rituximab (R)-bendamustine(B) has shown to be effective in terms of overall response rate (ORR), progression-free survival…”
Get full text

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial by Peñalver Párraga, Francisco Javier, Márquez Navarro, José Antonio, Durán Nieto, Soledad, Giraldo Castellano, Pilar, Montalbán Sanz, Carlos, Ramírez Sánchez, María José, Sancho Cia, Juan-Manuel, Terol Castera, María José, Capote Huelva, Francisco Javier, Gutiérrez García, Antonio, Sánchez González, Blanca, Salar Silvestre, Antonio, Canales Albendea, Miguel, Caballero Barrigón, María Dolores

“…Objectives: To evaluate the efficacy and toxicity of a response-adapted therapy with rituximab/bendamustine/mitoxantrone/dexamethasone (RBMD), followed by…”
Get full text

Prognostic Impact of the New CLL-IPI Index in a Single Center CLL Spanish Cohort by Ferrer Lores, Blanca, Navarro Cubells, Blanca, Serrano Alcala, Alicia, Castillo Martin, Ivan, Teruel Casasus, Anabel, Ballester Martinez, Sandra, Perez Martinez, Ariadna, Mauricio Campos, Ana, Castillo Valero, Inmaculada, Cano Gracia, Horacio, Solano Vercet, Carlos, Terol Casterá, María José

“…The hallmark for Chroniclymphocytic leukemia (CLL) is a highly variable clinical course. An international prognostic index (CLL-IPI) is a promising tool to…”
Get full text